Nevertheless, some studies indicate that about 40% of IBD patients have been identified as non-responding to treatment and many of anti-TNFα-treated patients are developing resistance for anti-TNFα monoclonal antibody3. The gene discussed is TNF; the disease is irritable bowel syndrome.